Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of once-weekly polyethylene glycol loxenatide in type 2 diabetes
ChiCTR1900026514Phase 4Not yet recruiting
- Sponsor
- Shantou Longhu People's Hospital
- Start
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Shantou Longhu People's Hospital. Primary endpoints: Blood glucose control, Insulin resistance and 2 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900026514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026514.